In a groundbreaking decision, the FDA has lifted the black box warnings on hormone replacement therapy for menopause, potentially improving access for women seeking relief from menopausal symptoms.
The Trump administration has sparked debate by proposing restrictions on one medication linked to autism, while advocating for broader access to another under investigation. What does this mean for future healthcare decisions?